BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32949967)

  • 1. Malignant peripheral nerve sheath tumors - Outcomes and prognostic factors based on the reference center experience.
    Sobczuk P; Teterycz P; Czarnecka AM; Świtaj T; Koseła-Paterczyk H; Kozak K; Falkowski S; Goryń T; Zdzienicki M; Morysiński T; Rutkowski P
    Surg Oncol; 2020 Dec; 35():276-284. PubMed ID: 32949967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
    Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
    J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant peripheral nerve sheath tumor with analysis of various prognostic factors: A single-institutional experience.
    Sharma MR; Puj KS; Salunke AA; Pandya SJ; Gandhi JS; Parikh AR
    J Cancer Res Ther; 2021; 17(1):106-113. PubMed ID: 33723140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).
    Valentin T; Le Cesne A; Ray-Coquard I; Italiano A; Decanter G; Bompas E; Isambert N; Thariat J; Linassier C; Bertucci F; Bay JO; Bellesoeur A; Penel N; Le Guellec S; Filleron T; Chevreau C
    Eur J Cancer; 2016 Mar; 56():77-84. PubMed ID: 26824706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant peripheral nerve sheath tumors of the spine: results of surgical management from a multicenter study.
    Chou D; Bilsky MH; Luzzati A; Fisher CG; Gokaslan ZL; Rhines LD; Dekutoski MB; Fehlings MG; Ghag R; Varga P; Boriani S; Germscheid NM; Reynolds JJ;
    J Neurosurg Spine; 2017 Mar; 26(3):291-298. PubMed ID: 27834629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST.
    Miao R; Wang H; Jacobson A; Lietz AP; Choy E; Raskin KA; Schwab JH; Deshpande V; Nielsen GP; DeLaney TF; Cote GM; Hornicek FJ; Chen YE
    Radiother Oncol; 2019 Aug; 137():61-70. PubMed ID: 31078939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.
    LaFemina J; Qin LX; Moraco NH; Antonescu CR; Fields RC; Crago AM; Brennan MF; Singer S
    Ann Surg Oncol; 2013 Jan; 20(1):66-72. PubMed ID: 22878618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical signs of neurofibromatosis impact on the outcome of malignant peripheral nerve sheath tumors.
    Lamm W; Schur S; Köstler WJ; Funovics P; Windhager R; Amann G; Panotopoulos J; Pokrajac B; Brodowicz T
    Oncology; 2014; 86(2):122-6. PubMed ID: 24480823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.
    Zou C; Smith KD; Liu J; Lahat G; Myers S; Wang WL; Zhang W; McCutcheon IE; Slopis JM; Lazar AJ; Pollock RE; Lev D
    Ann Surg; 2009 Jun; 249(6):1014-22. PubMed ID: 19474676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location.
    Kamran SC; Howard SA; Shinagare AB; Krajewski KM; Jagannathan JP; Hornick JL; Ramaiya NH
    Eur J Surg Oncol; 2013 Jan; 39(1):46-52. PubMed ID: 23084090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant peripheral nerve sheath tumors: Analysis of the national cancer database.
    Mowery A; Clayburgh D
    Oral Oncol; 2019 Nov; 98():13-19. PubMed ID: 31525622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy.
    Moretti VM; Crawford EA; Staddon AP; Lackman RD; Ogilvie CM
    Am J Clin Oncol; 2011 Aug; 34(4):417-21. PubMed ID: 20838322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study.
    Kroep JR; Ouali M; Gelderblom H; Le Cesne A; Dekker TJA; Van Glabbeke M; Hogendoorn PCW; Hohenberger P
    Ann Oncol; 2011 Jan; 22(1):207-214. PubMed ID: 20656792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors.
    Owosho AA; Estilo CL; Huryn JM; Chi P; Antonescu CR
    Head Neck Pathol; 2018 Jun; 12(2):151-159. PubMed ID: 28762137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric and adult malignant peripheral nerve sheath tumors: an analysis of data from the surveillance, epidemiology, and end results program.
    Amirian ES; Goodman JC; New P; Scheurer ME
    J Neurooncol; 2014 Feb; 116(3):609-16. PubMed ID: 24390465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant Peripheral Nerve Sheath Tumors of the Brachial Plexus: A Single-Center Experience on Diagnosis, Management, and Outcomes.
    Donaldson EK; Winter JM; Chandler RM; Clark TA; Giuffre JL
    Ann Plast Surg; 2023 Apr; 90(4):339-342. PubMed ID: 36752552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population.
    Patrizi S; Miele E; Falcone L; Vallese S; Rossi S; Barresi S; Giovannoni I; Pedace L; Nardini C; Masier I; Abballe L; Cacchione A; Russo I; Di Giannatale A; Di Ruscio V; Salgado CM; Mastronuzzi A; Ciolfi A; Tartaglia M; Milano GM; Locatelli F; Alaggio R
    Clin Epigenetics; 2024 Jan; 16(1):9. PubMed ID: 38178234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1.
    Hwang IK; Hahn SM; Kim HS; Kim SK; Kim HS; Shin KH; Suh CO; Lyu CJ; Han JW
    Cancer Res Treat; 2017 Jul; 49(3):717-726. PubMed ID: 28052660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
    Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.